Groupe Francophone Des Myelodysplasies
Groupe Francophone Des Myelodysplasies is recorded as a service provider in 1 clinical trial. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 1 of 1 trials · Latest update first
A phase II, open-label, multicenter study of orally administered RVU120 for the treatment of anemia in patients with lower-risk myelodysplastic neoplasms (MDS)
Sponsor GCP-Service International West GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Groupe Francophone Des Myelodysplasies?
The 2026-10-09 snapshot links Groupe Francophone Des Myelodysplasies to 1 distinct CTIS trials. Recorded services include Investigator recruitment, Medical expertise. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Groupe Francophone Des Myelodysplasies?
Therapeutic-area tags are not recorded in this snapshot. Study-phase tags are not recorded. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Groupe Francophone Des Myelodysplasies conducted?
The linked trials record locations in 5 countries, including Germany, Spain, France, Italy, Poland. These are trial locations, not confirmed office locations or countries where Groupe Francophone Des Myelodysplasies delivered services.
What can this page tell me about Groupe Francophone Des Myelodysplasies's trial experience?
Browse 1 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Groupe Francophone Des Myelodysplasies. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Groupe Francophone Des Myelodysplasies